Patents Assigned to DENALI THERAPEUTICS, INC.
-
Publication number: 20230092681Abstract: Certain embodiments provide a method of treating Hunter syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of a pharmaceutical composition comprising an ETV:IDS protein.Type: ApplicationFiled: February 5, 2021Publication date: March 23, 2023Applicant: DENALI THERAPEUTICS INC.Inventors: Annie ARGUELLO, Heather CAHAN, Vinay M. DARYANI, Anita GROVER, Matthew D. TROYER
-
Publication number: 20230062800Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.Type: ApplicationFiled: June 30, 2022Publication date: March 2, 2023Applicant: DENALI THERAPEUTICS INC.Inventors: Tina GIESE, Gunasekaran KANNAN, Mihalis KARIOLIS, Cathal MAHON
-
Patent number: 11591316Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.Type: GrantFiled: August 13, 2021Date of Patent: February 28, 2023Assignee: Denali Therapeutics Inc.Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
-
Publication number: 20230043400Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.Type: ApplicationFiled: February 25, 2021Publication date: February 9, 2023Applicant: Denali Therapeutics Inc.Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
-
Publication number: 20220249479Abstract: The present disclosure relates to modified release formulations of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-IH-pyrazol-1-propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts thereof, and methods of treatment with the modified release formulations.Type: ApplicationFiled: May 29, 2020Publication date: August 11, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Harish RAVIVARAPU, Travis REMARCHUK, Anantha SUDHAKAR, Bradley K. WONG
-
Publication number: 20220220172Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.Type: ApplicationFiled: March 18, 2022Publication date: July 14, 2022Applicant: Denali Therapeutics Inc.Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L.Y. Low, Rachel Prorok, Ankita Srivastava
-
Publication number: 20220220094Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.Type: ApplicationFiled: April 10, 2020Publication date: July 14, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney
-
Publication number: 20220213155Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.Type: ApplicationFiled: March 17, 2022Publication date: July 7, 2022Applicant: Denali Therapeutics Inc.Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L.Y. Low, Rachel Prorok, Ankita Srivastava
-
Patent number: 11370832Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.Type: GrantFiled: August 16, 2019Date of Patent: June 28, 2022Assignee: Denali Therapeutics Inc.Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
-
Publication number: 20220184186Abstract: Certain embodiments provide a pharmaceutical composition comprising: a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide; a buffer; an isotonicity agent; a surfactant; and a stabilizer; wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, as well as methods of use thereof.Type: ApplicationFiled: April 3, 2020Publication date: June 16, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Dana ANDERSEN, Adam CATHERMAN, Tina GIESE, Gunasekaran KANNAN, Mihalis KARIOLIS, Cathal MAHON, Ankit PATEL
-
Publication number: 20220153728Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.Type: ApplicationFiled: February 1, 2022Publication date: May 19, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Anthony A. Estrada, Jianwen A. Feng, Javier De Vicente Fidalgo, Zachary K. Sweeney
-
Publication number: 20220135546Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.Type: ApplicationFiled: August 13, 2021Publication date: May 5, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
-
Publication number: 20220119522Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.Type: ApplicationFiled: August 16, 2021Publication date: April 21, 2022Applicant: Denali Therapeutics Inc.Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
-
Publication number: 20220119371Abstract: Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: December 29, 2021Publication date: April 21, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
-
Patent number: 11306077Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.Type: GrantFiled: May 28, 2021Date of Patent: April 19, 2022Assignee: Denali Therapeutics Inc.Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
-
Publication number: 20220073609Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.Type: ApplicationFiled: August 16, 2021Publication date: March 10, 2022Applicant: Denali Therapeutics Inc.Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
-
Publication number: 20220041620Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.Type: ApplicationFiled: October 26, 2021Publication date: February 10, 2022Applicant: Denali Therapeutics Inc.Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
-
Patent number: 11236100Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.Type: GrantFiled: August 8, 2018Date of Patent: February 1, 2022Assignee: Denali Therapeutics Inc.Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
-
Publication number: 20220024938Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.Type: ApplicationFiled: October 5, 2021Publication date: January 27, 2022Applicant: Denali Therapeutics Inc.Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
-
Publication number: 20220025039Abstract: Certain embodiments described herein provide a method for treating dysregulated lipid metabolism and/or inflammation in a mammal in need thereof, comprising administering to the mammal an effective amount of an agonist anti-triggering receptor expressed on myeloid cells 2 (TREM2) antibody.Type: ApplicationFiled: November 26, 2019Publication date: January 27, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Giuseppe ASTARITA, Gilbert DI PAOLO, Kai Lin LIN, Kathryn M. MONROE, Alicia A. NUGENT, Bettina VAN LENGERICH